Brain phenylalanine concentration in the management of adults with phenylketonuria

R A Moats1, R Koch, K Moseley

  • 1Children's Hospital of Los Angeles, Division of Medical Genetics and Neuroradiology 90027, USA.

Insights

Measuring brain phenylalanine levels in phenylketonuria (PKU) patients may improve clinical decisions. Exceptional patients with high blood phenylalanine but good IQs had lower brain levels, suggesting brain measurement is key for managing PKU.

Area of Science:

  • Biochemistry
  • Neurology
  • Genetics

Background:

  • Newborn screening and phenylalanine-restricted diets enable normal development in most phenylketonuria (PKU) patients.
  • Dietary recommendations for PKU vary, especially for adults, due to factors like quality of life, cost, and genetics.
  • Current methods like molecular analysis and MRI lack clear correlations for PKU management.

Purpose of the Study:

  • To investigate the direct measurement of brain phenylalanine levels as a tool for clinical decision-making in PKU management.
  • To explore the relationship between blood and brain phenylalanine concentrations in PKU patients.

Main Methods:

  • Simultaneous measurement of blood and brain phenylalanine levels in 21 PKU subjects.
  • Inclusion of randomly selected patients, clinically examined patients, and exceptional patients with high IQs despite high historical blood phenylalanine levels.

Main Results:

  • A generally poor correlation was observed between blood and brain phenylalanine concentrations.
  • Four exceptional patients with high IQs and high historical blood phenylalanine showed relatively low brain phenylalanine levels.
  • This suggests that low brain phenylalanine levels may explain good clinical status in some PKU patients.

Conclusions:

  • Direct measurement of brain phenylalanine concentration appears useful for managing PKU patients.
  • This approach may offer better insights than blood levels alone, especially for adults and those with historical dietary non-adherence.

Related Concept Videos

Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...